Literature DB >> 10524966

Molecular epidemiology of the global and temporal diversity of Candida albicans.

M J McCullough1, K V Clemons, D A Stevens.   

Abstract

The epidemiology of Candida albicans has changed with the rise in immunocompromised patients and the pressures of antifungal treatment and prophylaxis. We assessed the genotype distribution of recently obtained, globally diverse isolates in comparison with isolates recovered in the United States and United Kingdom before 1985, in order to determine temporal and geographic differences. We used EcoRI digestion of cellular DNA to generate restriction fragment length polymorphisms, dividing the isolates into 4 groups. From 15 diverse geographic areas, 439 isolates obtained over 20 years were divided into 121 genotypes within groups A (289 isolates), B (85), C (56), and D (9). Differences in genotype distribution existed among the localities (P<.0001) and between isolates obtained before 1990 versus those recovered since then (P=.009). Comparison of pre-1985 United States/United Kingdom isolates with post-1994 United States isolates revealed a trend toward a changing genotype distribution (P=.057). Global post-1985 isolates were different in genotype distribution from United States/United Kingdom isolates (P<.0001). The distribution of isolates from Israel was unique (P<.0001). These differences could be due in part to the increasing prevalence of group C strains worldwide.

Entities:  

Mesh:

Year:  1999        PMID: 10524966     DOI: 10.1086/313455

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  First report of Candida dubliniensis in the Middle East.

Authors:  D A Stevens
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

2.  Molecular epidemiology of Candida.

Authors:  David A Stevens
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

3.  Molecular analysis and susceptibility profiling of Candida albicans isolates from immunocompromised patients in South India.

Authors:  C P Girish Kumar; Ahmed Medhat Hanafy; Masakazu Katsu; Yuzuru Mikami; Thangam Menon
Journal:  Mycopathologia       Date:  2006-03       Impact factor: 2.574

4.  Molecular phylogenetics of Candida albicans.

Authors:  Frank C Odds; Marie-Elisabeth Bougnoux; Duncan J Shaw; Judith M Bain; Amanda D Davidson; Dorothée Diogo; Mette D Jacobsen; Maud Lecomte; Shu-Ying Li; Arianna Tavanti; Martin C J Maiden; Neil A R Gow; Christophe d'Enfert
Journal:  Eukaryot Cell       Date:  2007-04-06

5.  Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral candidiasis without culture evidence.

Authors:  Brenda A McManus; Eleanor McGovern; Gary P Moran; Claire M Healy; June Nunn; Pádraig Fleming; Colm Costigan; Derek J Sullivan; David C Coleman
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

Review 6.  Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment.

Authors:  Natália Martins; Isabel C F R Ferreira; Lillian Barros; Sónia Silva; Mariana Henriques
Journal:  Mycopathologia       Date:  2014-05-01       Impact factor: 2.574

7.  Genotypic differences of Candida albicans and C. dubliniensis isolates related to ethnic/racial differences within the same geographic area.

Authors:  Michael J McCullough; Jacks J Jorge; Flavio Lejbkowicz; Eli Lefler; Faris Nassar; Karl V Clemons; David A Stevens
Journal:  Mycopathologia       Date:  2004-07       Impact factor: 2.574

8.  Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies.

Authors:  Eveline C van Asbeck; Yhu-Chering Huang; Angela N Markham; Karl V Clemons; David A Stevens
Journal:  Mycopathologia       Date:  2007-09-15       Impact factor: 2.574

9.  Molecular analysis of Candida albicans isolates from clinical specimens.

Authors:  Melahat Gurbuz; Ilknur Kaleli
Journal:  Mycopathologia       Date:  2009-12-10       Impact factor: 2.574

10.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.